SUPN executive reports RSU award and tax withholding

SUPERNUS PHARMACEUTICALS, INC.

Accepted by SEC EDGAR 02/26/2026 - 04:18 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. Sr. VP of IP and CSO Padmanabh P. Bhatt reported equity award-related transactions. A grant of 1,250 shares of common stock was acquired at a price of $0.00, tied to restricted stock units that convert into one share each upon vesting.

On the same date, 1,250 restricted stock units were disposed back to the issuer and 650 shares of common stock at $50.69 were withheld by the company to cover tax obligations in connection with RSU vesting, rather than sold on the open market.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Bhatt Padmanabh P.

Role Sr. VP of IP, CSO

Type	Security	Shares	Price	Value
Disposition	Restricted Stock Unit	1,250	$0.00	$0.00
Grant/Award	Common Stock	1,250	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	650	$50.69	$33K

Holdings After Transaction: Restricted Stock Unit — 1,250 contracts (Direct); Common Stock — 17,044 shares (Direct)

Holdings Before and After: Restricted Stock Unit, 2,500 to 1,250 contracts (Direct); Common Stock, 16,444 to 17,044 shares (Direct)

Footnotes (3)

1. F1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
2. F2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
3. F3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SUPN executive Padmanabh P. Bhatt report on this Form 4?

Padmanabh P. Bhatt reported three equity-related transactions: a grant of 1,250 common shares at $0.00, a disposition of 1,250 restricted stock units to the issuer, and 650 common shares withheld at $50.69 to satisfy tax obligations from RSU vesting.

Were any SUPN shares in this Form 4 sold on the open market?

No open-market sales were reported. The 650 common shares at $50.69 were withheld by the company to pay tax obligations related to restricted stock unit vesting, rather than sold in a market transaction, according to the transaction code F and related footnote.

What does the restricted stock unit grant to SUPN’s Padmanabh P. Bhatt represent?

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These RSUs are settled in common stock and vest in four equal annual installments starting on February 23, 2024, aligning compensation with ongoing service and performance.

How did these transactions affect Padmanabh P. Bhatt’s SUPN common stock holdings?

After the 1,250-share grant and 650-share tax withholding, Padmanabh P. Bhatt directly held 17,044 shares of SUPERNUS common stock. This figure reflects the net position following the reported award acquisition and the tax-withholding disposition tied to the vesting event.

Why did SUPN withhold 650 shares from Padmanabh P. Bhatt in this filing?

The 650 common shares were withheld to satisfy tax withholding requirements triggered by the vesting of restricted stock units. Instead of paying taxes in cash, a portion of the vested shares was delivered back to the company to meet the associated tax liability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhatt Padmanabh P.

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP of IP, CSO

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		A		1,250	A	$0	17,694	D
Common Stock	02/25/2026		F		650(1)	D	$50.69	17,044	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	02/25/2026		D			1,250	(3)	(3)	Common Stock	1,250	$0	1,250	D

Explanation of Responses:

1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.

2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.